Phytomedicine : international journal of phytotherapy and phytopharmacology · 2026
Unveiling the pharmacological basis of Rhodiola crenulata for atopic dermatitis: A multi-model approach combining zebrafish, mouse studies, and intelligent computational analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Xiongyi, Wang Yanfu, Zhao Dongyang, Yin Cong, Wu Haoyuan, Zeng Jin, Shi Xueyan, He Menglian, Feng Guangchuan, Wang Yonglin, Liu Jingxin, Huang Weihuan, Tian Haiyan
Аннотация
BACKGROUND: Atopic dermatitis (AD) is a complex inflammatory skin disorder. Rhodiola crenulata extract (RC) contains bioactive compounds with potential benefits for AD, but its mechanisms are not fully elucidated.
METHODS: A DNCB-induced AD mouse model and zebrafish models were used to evaluate efficacy and multi-dimensional activities. RC was separated into microfractions by preparative liquid chromatography. An OPLS-DA model, based on zebrafish bioactivity and LC-MS profiling, predicted active compounds, which were validated. Mechanisms were investigated via transcriptome sequencing, Western blot, qPCR, network pharmacology, and molecular docking.
RESULTS: RC alleviated AD-like symptoms in mice, reducing epidermal thickening, mast cell infiltration, and splenomegaly. Four active monomers were identified, with kaempferol and naringenin showing the most prominent anti-inflammatory and analgesic effects, while salidroside exhibited strong antioxidant activity. RC and its active components primarily inhibited the NLRP3/Caspase-1/IL-1β axis, while also modulating oxidative stress (e.g., NOX2, PRDX2), cAMP/PKA signaling, and skin barrier-repair pathways. Network pharmacology and molecular docking confirmed efficient binding of four core compounds to NLRP3, CASP1, and IL-1B.
CONCLUSION: This study demonstrates that RC alleviates AD by inhibiting the NLRP3 inflammasome pathway, identifying kaempferol, naringenin, salidroside and rhodiosin as key constituents, providing a foundation for developing RC as a natural AD therapeutic.
METHODS: A DNCB-induced AD mouse model and zebrafish models were used to evaluate efficacy and multi-dimensional activities. RC was separated into microfractions by preparative liquid chromatography. An OPLS-DA model, based on zebrafish bioactivity and LC-MS profiling, predicted active compounds, which were validated. Mechanisms were investigated via transcriptome sequencing, Western blot, qPCR, network pharmacology, and molecular docking.
RESULTS: RC alleviated AD-like symptoms in mice, reducing epidermal thickening, mast cell infiltration, and splenomegaly. Four active monomers were identified, with kaempferol and naringenin showing the most prominent anti-inflammatory and analgesic effects, while salidroside exhibited strong antioxidant activity. RC and its active components primarily inhibited the NLRP3/Caspase-1/IL-1β axis, while also modulating oxidative stress (e.g., NOX2, PRDX2), cAMP/PKA signaling, and skin barrier-repair pathways. Network pharmacology and molecular docking confirmed efficient binding of four core compounds to NLRP3, CASP1, and IL-1B.
CONCLUSION: This study demonstrates that RC alleviates AD by inhibiting the NLRP3 inflammasome pathway, identifying kaempferol, naringenin, salidroside and rhodiosin as key constituents, providing a foundation for developing RC as a natural AD therapeutic.